Genomic Health, Pfizer To Develop Prognostic Test For Non-Metastatic Renal Cell Carcinoma
Non-Metastatic Renal Cell Carcinoma Test
Genomic Health, Pfizer to develop a genomic test to estimate the risk of recurrence following surgery for patients with Stage I-III renal carcinoma, clear cell type, that has not spread to other parts of the body.
The clear cell type of renal carcinoma is the most common type of kidney cancer in adults, affecting an estimated 25,000 people each year in the United States. As part of the collaboration, the companies will apply the same molecular technology and clinical strategy Genomic Health used to develop its Oncotype DX breast cancer test.
"Working together with Pfizer, we have the potential to address a serious unmet need," said Chu Chang, Genomic Health's Vice President of Business Development.
"Many early-stage renal carcinoma patients experience a recurrence of their cancer, yet there is no accurate way to identify the most aggressive cancers in advance. This collaboration further expands our efforts to develop genomic tests for a variety of cancers that allow physicians and patients to individualize treatment decisions."